CTNNB1 and colonic neoplasm: We used two different doxycycline-induced shRNAs against CTNNB1 to study effects of antagonizing CTNNB1 endogenous transcript levels in the DLD1 human colon cancer cell line, which harbor APC defects leading to constitutive activation of β-catenin/TCF signaling (Fig 6B).